| 5.69 5.69 (23.97%) | 04-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.14 | 1-year : | 11.97 |
| Resists | First : | 7.83 | Second : | 10.25 |
| Pivot price | 5.39  |
|||
| Supports | First : | 3.92 | Second : | 3.26 |
| MAs | MA(5) : | 4.77 |
MA(20) : | 6.04 |
| MA(100) : | 18.01 |
MA(250) : | 23.22 |
|
| MACD | MACD : | -1.2 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 25.2 |
D(3) : | 18.5 |
| RSI | RSI(14): 43 |
|||
| 52-week | High : | 71.5 | Low : | 3.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BCAB ] has closed below upper band by 45.8%. Bollinger Bands are 62.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 42 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.6 - 5.63 | 5.63 - 5.66 |
| Low: | 4.52 - 4.55 | 4.55 - 4.57 |
| Close: | 5.55 - 5.6 | 5.6 - 5.64 |
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Fri, 17 Apr 2026
BCAB Stock Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
Fri, 03 Apr 2026
BioAtla Announces 1-for-50 Reverse Stock Split Merger - The Globe and Mail
Thu, 02 Apr 2026
[8-K] BioAtla, Inc. Reports Material Event - Stock Titan
Tue, 31 Mar 2026
BioAtla shrinks share count 50-for-1 to meet Nasdaq's $1 bid rule - Stock Titan
Tue, 31 Mar 2026
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Investing News Network
Tue, 31 Mar 2026
With $7.1M cash, BioAtla weighs asset sales and slower trial pacing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 20.4 (%) |
| Shares Short | 47 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | -50.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -28.52 |
| Profit Margin | 0 % |
| Operating Margin | -462.8 % |
| Return on Assets (ttm) | -110.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -24.75 |
| Sales Per Share | 1.2 |
| EBITDA (p.s.) | -35.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -48 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | -0.2 |
| Price to Sales | 4.64 |
| Price to Cash Flow | -0.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|